AstraZeneca sought our help as it right-sized its global R&D capabilities with the loss of over 7,000 roles. We supported the organisation’s leadership in delivering this transformation programme across 9 countries.
We helped to distill and articulate the business rationale and future intent for global R&D operations, supported internal teams and trained the organisation’s communicators, enabling them to deliver tough news with sensitivity and precision.
It was critical that, despite multiple site closures and job losses, the business retained the ability to maintain its drug pipeline momentum. Feedback from staff showed appreciation for the sensitive manner in which the news was communicated, which established trust for the company’s next growth phase.
